Dr Quintana approached InVivo Biosystems wanting to collaborate on three independent projects that each targeted a different region or domain of the protein HFC1. HFC1 is of particular interest to Quintana because it is a gene that is associated with intellectual disability and manifests during the developmental period. The end goal of the three projects was to compare how different gene mutations would differ in their disruption of neural precursors. 

Dr. Quintana chose to leverage InVivo Biosystems’ fully validated custom injection mixes to create point mutations that target the protein HFC1 in zebrafish. InVivo Biosystems worked with Dr. Quintana’s lab to design the mixes, and provided her lab with the validation protocol. Consequently, Quintana’s lab was able to generate F1 heterozygous carriers from the fully validated mixes, and then, used InVivo’s screening reagents to identify carriers with the precise germline edit within a matter of weeks.